We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Status: Active

Apr 9th 2021 - May 10th 2021

Alyve provides personalised subscription nutrition powered by Artificial Intelligence (AI). It argues that 8.2 million UK vitamin users are looking for personalised nutrition in one capsule. Alyve asserts that its product can fulfil this demand. Users complete a 3-minute questionnaire where their responses are recorded by Alyve's intelligent algorithms. These then, based on the responses, help the user select one of Alyve's nutritional pills best matched to their goals and needs. Alyve then delivers the pills to the user's doorstep every 30 days. The company has recorded 4000+ questionnaires and completed 800+ orders in 25 countries since Q4 of 2020. It aims to become a contender in the $21 billion supplement market. The company will use the investment received to increase marketing efforts, transform Alyve into a household brand, introduce new product lines, increase staff, improve technology, and transform both digital and physical User Experiences (UX).

read more read less

Alyve Rating Review

Pitch rating powered by CROWDRATING

Rated on 29/04/2021

Pitch Rated

80%

Gold

Management

84%

Product

75%

Investment

80%

Log in to view amount pledged

    Log in to view target

    £1,500,367
    pre-money valuation

    9.09%
    equity available

    222
    investors

    £1,026
    pledge per investor

    12340284
    company number

    Active
    company status

    29/11/2019
    incorporated 4 years

    £7.50
    share price

    Previous Funding rounds
    28 Mar 24 Crowdcube £227,782 / 152% 79.67%

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 84%

Skills 82%
The Alyve management team are described as having the skills of business, marketing, nutrition, start-ups, healthcare, and media relations as per their reported LinkedIn profiles. The Co-Founder/CEO has previously worked at the same stage and is skilled in entrepreneurship, marketing, and networking. The Co-Founder/COO has previously worked in the healthcare sector and appears to be proficient in coaching, laboratory testing, health promotion and ill-health prevention, and team building. The Head of Nutrition is a Naturopathic Nutritional Therapist. The Head of Partnerships is a brand specialist skilled in public relations, social media, and corporate communications. She has been awarded the weight loss of the year award at Alyve. The management team has outsourced the technical expertise for the AI-based platform, and they intend to hire a CTO after the successful completion of this round.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


More from Health and Fitness

Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000

Log in to view amount pledged

    Log in to view target

    £1,500,367
    pre-money valuation

    9.09%
    equity available

    222
    investors

    £1,026
    pledge per investor

    12340284
    company number

    Active
    company status

    29/11/2019
    incorporated 4 years

    £7.50
    share price

    Previous Funding rounds
    29 Mar 24 Crowdcube £227,782 / 152% 79.67%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph